Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse Clinical Trial

Official title:

Application of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05488132
• Other study ID #: XYFY2022-KL119-01
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 1, 2022
• Est. completion date: March 31, 2025

Study information

• Verified date: March 2022
• Source: Xuzhou Medical University
• Contact: Kailin Xu, M.D., Ph.D.
• Phone: 15162166166
• Email: lihmd[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.

Description:

Sialic acid-binding immunoglobulin-like lectins (Siglec) are a class of classical immunoglobulin-like lectins. Studies have shown that Siglec-6 is commonly expressed in AML but not detected on normal hematopoietic stem and progenitor cells (HSC/P). In vitro experiments revealed that anti-Siglec-6 CAR-T cell treatment did not affect the viability or lineage differentiation in colony-forming assays. These data suggest that anti-SigLlec-6 is an ideal target with great potential for treating acute myeloid leukemia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: March 31, 2025
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. All subjects must sign and date the Informed Consent before initiating any study specific procedures or activities;

2. At the age of 18-70 years old;

3. Diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML);

4. The patient has recovered from the toxicity of previous treatment;

5. ECOG score = 2 and expected survival period is not less than 3 months;

6. Adequate organ function defined as:AST =3×ULN; ALT =3×ULN; Total bilirubin =1.5×ULN; Serum creatinine =1.5×ULN, or CCR=60 mL/min; Hemoglobin =60g/L ; Indoor oxygen saturation =92%; LVEF=45%;

7. Pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test;

8. From the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception.

Exclusion Criteria:

1. Diagnosis of acute promyelocytic leukemia;

2. History or presence of a CNS disorder;

3. HBsAg is positive; HCV ?HIV or Syphilis antibody are positive, CMV DNA in peripheral blood is more than=500 copies /mL;

4. History of severe hypersensitivity reaction;

5. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment;

6. History of organ transplant surgery;

7. Required systemic application of immunosuppressive or other drugs;

8. Auto-SCT within the 3 months before enrollment;

9. Active autoimmune or inflammatory diseases of the nervous system (e.g., Guillain-Barre syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (PRES));

10. Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (TLS)) ;

11. Presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management;

12. Live vaccine received within the = 4 weeks before enrollment;

13. Persons with serious mental illness;

14. History of major surgical operations four weeks before enrollment;

15. History of alcoholism or substance abuse;

16. Was identified by the investigators as unsuitable to participate in the study.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia Refractory
• Acute Myeloid Leukemia, in Relapse
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• anti-siglec-6 CAR-T cell therapy
Enrolled patients will receive prespecified dose of autologous CAR-T cells.

Locations

Country	Name	City	State
China	Kailin Xu	Xuzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Xuzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicity(DLT)	Adverse events assessed according to NCI-CTCAE v5.0 criteria	Baseline up to 28 days after T cell infusion
Secondary	MRD negative overall response rate (MRD- ORR)	Assessment of MRD negative overall response rate (MRD- ORR) at 3 months of treatment	3 months
Secondary	Overall response rate (ORR)	Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24	Month 6, 12, 18 and 24
Secondary	Event-free survival (EFS)	Assessment of EFS at Month 6, 12, 18 and 24	Month 6, 12, 18 and 24
Secondary	Overall survival (OS)	Assessment of OS at Month 6, 12, 18 and 24	Time Frame: Month 6, 12, 18 and 24